Related Experiment Video
Updated: Apr 6, 2026

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails
Sumudu Katugampola1, Jianchao Wang1, Roger W Howell2
1Division of Radiation Research, Department of Radiology, New Jersey Medical School, Rutgers University, Newark, New Jersey.
Abstract:
Radiopharmaceutical cocktails have been developed over the years to treat cancer. Cocktails of agents are attractive because 1 radiopharmaceutical is unlikely to have the desired therapeutic effect because of nonuniform uptake by the targeted cells. Therefore, multiple radiopharmaceuticals targeting different receptors on a cell is warranted. However, past implementations in vivo have not met with convincing results because of the absence of optimization strategies. Here we present artificial intelligence (AI) tools housed in a new version of our software platform, MIRDcell V4, that optimize a cocktail of radiopharmaceuticals by minimizing the total disintegrations needed to achieve a given surviving fraction (SF) of tumor cells. Methods: AI tools are developed within MIRDcell V4 using an optimizer based on the sequential least-squares programming algorithm. The algorithm determines the molar activities for each drug in the cocktail that minimize the total disintegrations required to achieve a specified SF. Tools are provided for populations of cells that do not cross-irradiate (e.g., circulating or disseminated tumor cells) and for multicellular clusters (e.g., micrometastases). The tools were tested using model data, flow cytometry data for suspensions of single cells labeled with fluorochrome-labeled antibodies, and 3-dimensional spatiotemporal kinetics in spheroids for fluorochrome-loaded liposomes. Results: Experimental binding distributions of 4 211At-antibodies were considered for treating suspensions of MDA-MB-231 human breast cancer cells. A 2-drug combination reduced the number of 211At decays required by a factor of 1.6 relative to the best single antibody. In another study, 2 radiopharmaceuticals radiolabeled with 195mPt were each distributed lognormally in a hypothetical multicellular cluster. Here, the 2-drug combination required 1.7-fold fewer decays than did either drug alone. Finally, 2 225Ac-labeled drugs that provide different radial distributions within a spheroid require about one half of the disintegrations required by the best single agent. Conclusion: The MIRDcell AI tools determine optimized drug combinations and corresponding molar activities needed to achieve a given SF. This approach could be used to analyze a sample of cells obtained from cell culture, animal, or patient to predict the best combination of drugs for maximum therapeutic effect with the least total disintegrations.
Insights
Artificial intelligence (AI) tools in MIRDcell V4 optimize radiopharmaceutical cocktails to minimize radiation dose for cancer treatment. This AI approach enhances therapeutic efficacy by determining optimal drug combinations and activities for improved patient outcomes.
Area of Science:
- Nuclear medicine
- Computational biology
- Oncology
Background:
- Radiopharmaceutical cocktails are crucial for cancer therapy due to non-uniform cell uptake.
- Optimization strategies are needed to improve the efficacy of multi-agent radiopharmaceutical treatments.
- Previous in vivo implementations lacked convincing results due to the absence of optimization.
Purpose of the Study:
- To develop and present artificial intelligence (AI) tools for optimizing radiopharmaceutical cocktails.
- To minimize the total number of radioactive decays needed to achieve a specific tumor cell surviving fraction (SF).
- To provide tools for optimizing treatments for both single cells and multicellular tumor clusters.
Main Methods:
- AI tools were developed in MIRDcell V4 using a sequential least-squares programming algorithm.
- The algorithm identifies optimal molar activities for each drug in a cocktail to minimize total decays for a target SF.
- Tools were validated using model data, flow cytometry, and 3D spheroid models.
Main Results:
- A 2-drug combination reduced 211At decays by 1.6-fold compared to a single agent for breast cancer cells.
- In a hypothetical cluster, a 2-drug combination using 195mPt required 1.7-fold fewer decays than single agents.
- Two 225Ac-labeled drugs reduced required disintegrations by half compared to the best single agent.
Conclusions:
- MIRDcell AI tools effectively determine optimized drug combinations and molar activities for cancer therapy.
- This AI-driven approach can predict the best drug combinations for maximum therapeutic effect with minimal radiation exposure.
- The methodology holds potential for personalized cancer treatment by analyzing patient-specific cell samples.
More Related Videos
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022